Inflammation in atherosclerosis: from pathophysiology to practice
When to decrease dose Consider decreasing if: Persistent side effects that don't resolve Excellent results achieved and maintenance desired Budget constraints require conservation Stacking and wanting to optimize ratios Many researchers find they can reduce dose during maintenance phases after achieving initial goals during more intensive loading phases
Like Fer-1, Liproxstatin-1 (Lip-1) and Liproxstatin-2 (Lip-2) are ferroptosis inhibitors identified through small molecule screening (Friedmann Angeli et al., 2014
Both are cytosolic enzymes, whereas DPP-4 is processed by the Golgi apparatus and displayed on the surface of the cell where both GIP and GLP-1 act (Lankas et al., 2005)
With GLP-1 medications, this may happen due to delayed gastric emptying, which allows food to remain in the stomach longer, potentially leading to bacterial fermentation and gas production with a characteristic sulphurous odour
This is another example where it can be hard to separate the placebo effect